Daewoong Expands Collaboration with the University of Indonesia to Develop Medical Devices, Foster Talent, and Advance Medical Technology
(Jakarta, February 7th 2025) Daewoong continues its commitment to collaborative growth with Indonesia's pharmaceutical and biotech industries, a partnership that has spanned over two decades.
On January 24, Daewoong’s affiliate, CGBio (CEO Hyun-Seung Yu), announced the signing of an industry-academia collaboration agreement with the University of Indonesia (UI), widely recognized as the country's premier academic institution, through its Biomedical Engineering Research Center.
The partnership focuses on advancing medical device development by leveraging local resources and talent to establish a cutting-edge medical device ecosystem and enhance global competitiveness. The collaboration will also extend to fostering talent through internship and education programs. CGBio will work closely with the University of Indonesia to provide opportunities for local students and professionals to engage in research and production processes, equipping them with advanced technical knowledge and practical expertise in the field of medical devices.
Hyun-Seung Yu, CEO of CGBio said that “Witnessing the passion and outstanding achievements of local researchers firsthand, I am convinced that together we can drive global innovation,” and “By harnessing Indonesia’s rich resources and exceptional talent, we aim to develop groundbreaking technologies and nurture skilled professionals who will revolutionize the global medical industry. This collaboration aligns with our vision to secure a leading position in the global medical device market by 2030.”
Especially, CGBio plans to construct a new medical device manufacturing facility in Cikarang, Indonesia. Construction is scheduled to commence in December 2025, with the plant focusing on producing a range of essential medical devices for the Indonesian market, including bone graft substitutes and coronary stents. CGBio aims to significantly contribute to the Indonesian medical device manufacturing industry by pursuing the construction of this new factory, based on the results of its research collaboration with the University of Indonesia.
Moving forward, CGBio and the University of Indonesia will work closely to achieve three key goals: medical device research and development utilizing local resources, talent cultivation, and healthcare infrastructure advancement. Together, they aim to deliver long-term, sustainable success in the medical device industry.
Attending the signing ceremony, Eric Aoh, Business Head of CGBio Indonesia, also mentioned that “This partnership and research collaboration not only focus on advancing medical device development but also on fostering talent and improving healthcare infrastructure. We are committed to delivering sustainable outcomes for both local and global markets.”
Since 2018, Daewoong has expanded its research infrastructure by opening three laboratories: the Bio Technology Research Center in 2018, the Bio Analytic Center in 2022 at the University of Indonesia, and the Daewoong Drug Delivery System Laboratory at Institut Teknologi Bandung, launched in 2024. Notably, the two laboratories at the University of Indonesia have been conducting research on stem cell and biopharmaceutical treatments for Indonesia.
On the other hand, CGBio, a global leader in regenerative medicine and biotechnology, plans to implement a sustainable collaboration model that encompasses the development and commercialization of medical device materials using Indonesia’s abundant physical and human resources. This initiative is anticipated to drive not only technological advancements but also contribute to the growth of the local economy and healthcare industry.
- # # # -
